XENT News and Press, Intersect ENT Inc. From 08/06/21

Medtronic (NYSE:MDT) is trading ~1.4% higher in the pre-market after announcing an agreement to acquire Intersect ENT (NASDAQ:XENT) in an all-cash transaction valued at $1.1B including debt. Intersect ENT (XENT) is a MedTech player in the ear, nose, and throat (ENT) space with ...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into ...

Medtronic to Acquire Intersect ENT Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio Canada NewsWire DUBLIN and MENLO PARK, Calif. , Aug. 6, 2021 /CNW/ -- Medtronic plc (NYSE:MDT), the global leader...

VenSure and Cube Join the Company’s Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedi...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company expects to issue th...

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update. Second Quarter 2021 Overview Pr...

LeoPatrizi/iStock via Getty Images AmerisourceBergen buying Parexel is unlikely AmerisourceBergen (ABC) potentially acquiring contract research organization Parexel -- as has been suggested in media reports -- is highly unlikely, according to BofA Securities. Analyst Michael Cherny notes that...

Intersect ENT (XENT) has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union.PROPEL Contour is specifically designed to maintain patency and reduce inflammation, and conform to the sinu...

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient c...

Intersect ENT, Inc. (XENT) Q1 2021 Earnings Conference Call May 10, 2021 08:30 AM ET Company Participants Randy Meier - Executive Vice President & Chief Financial Officer Tom West - President & Chief Executive Officer Conference Call Participants Robbie Marcus - JPMorgan Richard Newit...